DEFINE Trial
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
DEFINE Trial On the Web |
|
American Roentgen Ray Society Images of DEFINE Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
- Various clinical trials[1][2] showed that anacetrapib significantly lowers LDL cholesterol and raises HDL levels without any increase in systolic blood pressure.
References
- ↑ Cannon CP, Dansky HM, Davidson M; et al. (2009). "Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib". American Heart Journal. 158 (4): 513–519.e3. doi:10.1016/j.ahj.2009.07.028. PMID 19781408. Unknown parameter
|month=ignored (help) - ↑ Krishna R, Anderson MS, Bergman AJ; et al. (2007). "Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies". Lancet. 370 (9603): 1907–14. doi:10.1016/S0140-6736(07)61813-3. PMID 18068514. Unknown parameter
|month=ignored (help)